Patients suspected of having blood cancers, immune system disorders, or those being monitored for treatment response may be advised to undergo this test.

It helps detect multiple myeloma, chronic lymphocytic leukemia, and other disorders involving abnormal plasma cells or lymphocytes.

Yes, CD38 expression may vary with disease progression or treatment, making repeated testing useful for monitoring patient response.

Yes, it is commonly used to identify abnormal plasma cells in multiple myeloma, aiding diagnosis, classification, and monitoring of disease progression.

Absolutely. It helps detect abnormal lymphocytes in chronic lymphocytic leukemia and provides insights into disease severity and treatment response.